Pharmaceutisch Weekblad

, Volume 9, Supplement 1, pp S82–S86 | Cite as

Quinolones in the treatment of gonorrhoea and Chlamydia trachomatis infections

  • E. Stolz
  • J. H. T. Wagenvoort
  • A. H. van der Willigen


The results of two therapeutic trials in female patients with uncomplicated urogenital gonorrhoea (A) and in male patients with uncomplicated urethral gonorrhoea (B) treated with either 200 mg and 400 mg enoxacin orally, of one therapeutic trial in male patients with uncomplicated urogenital gonorrhoea treated with either 250 mg or 500 mg ciprofloxacin orally (C) and of one therapeutic trial in male patients with non-gonococcal urethritis (NGU) treated with ciprofloxacin 1 g daily during seven days (D) are presented and compared with the results of other investigators. The cure rate in study A was 100% (n=40) in the 400 mg group and 95.7% (n=46) in the 200 mg group. The cure rate in study B was 92% (n=78) in the 400 mg group and 90% (n=77) in the 200 mg group. In both studies no antichlamydial effect of enoxacin was observed. The cure rates in study C were 100% with 250 and 500 mg. An antichlamydial effect seemed to be present. In studies A, B and C side effects were minor and rare and were mainly nausea and headache. In study D (100 patients suffering from NGU) disappearance ofChlamydia trachomatis andUreaplasma urealyticum one day after the end of treatment was observed in 29 of 32 (91 %) and 28 of 32 (88%) cases, respectively. Pyuria disappeared in 44% and 74% of the patients showed clinical cure. However, two weeks after the end of treatmentChlamydia trachomatis andUreaplasma urealyticum were observed in respectively six and eight cases. In 30% pyuria was still absent. Side effects were only minor. In conclusion, ciprofloxacin can be considered a drug of choice in uncomplicated urethral gonorrhoea. It may also be of value in NGU and in mixed gonococcal and chlamydial infections.

Key words

Chlamydia trachomatis Ciprofloxacin Enoxacin Neisseria gonorrhoea Quinolones Side effects Ureaplasma urealyticum Urethritis 


  1. 1.
    Gombert ME. The in vitro activity of quinolone antibiotics against pathogens causing sexually transmitted diseases. Infect Med Dis Lett Obstet Gynecol 1986;8:32–4.Google Scholar
  2. 2.
    Eijk RVW van. Personal communication.Google Scholar
  3. 3.
    Tegelberg-Stassen MJAM, Willigen AH van der, Hoek JC van der, Wagenvoort JHT, Vliet JH van, Klingeren B van, Joost TH van, Michel MF, Stolz E. Treatment of uncomplicated urogenital gonorrhoea in women with a single oral dose of enoxacin. Eur J Clin Microbiol 1986;5:395–8.PubMedGoogle Scholar
  4. 4.
    Willigen AH van der, Hoek JCS van der, Wagenvoort JHT, Vliet HJA van, Klingeren B van, Schalla WO, Knapp JC. A comparative double-blind study of 200 mg and 400 mg enoxacin given orally in the treatment of acute uncomplicated urethral gonorrhoea in males. Antimicrob Agents Chemother 1978;31:535–8.Google Scholar
  5. 5.
    Tegelberg-Stassen MJAM, Hoek JCS van der, Mooy L, Wagenvoort JHT, Joost TH van, Michel MF, Stolz E. Treatment of uncomplicated gonococcal urethritis in men with two dosages of ciprofloxacin. Eur J Clin Microbiol 1986;5:244–7.PubMedGoogle Scholar
  6. 6.
    Willigen AH van der, Wagenvoort JHT, Polak-Vogelzang AA, Habbema L, Joost TH van, Michel MF, Stolz E. Comparison of the clinical efficacy of ciprofloxacin and doxycycline in the treatment of non-gonococcal urethritis in men. Submitted for publication.Google Scholar
  7. 7.
    Stolz E, Zwart HGF, Michel MF. Sensitivity to ampicillin, penicillin and tetracycline of gonococci in Rotterdam. Br J Vener Dis 1974;50:202–4.PubMedGoogle Scholar
  8. 8.
    Shepard MC, Lunceford CO. Differential agar medium (A-7) for identification of Ureaplasma urealyticum (human T-mycoplasmas) in primary cultures of clinical material. J Clin Microbiol 1976;3:613–5.PubMedGoogle Scholar
  9. 9.
    Tjiam KH, Wagenvoort JHT, Klingeren B van, Piot P, Stolz E, Michel MF. In vitro activity of the two new 4-quinolones of A 56619 and A 56620 againstNeisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum andGardnerella vaginalis. Eur J Clin Microbiol 1986;5:498–501.PubMedGoogle Scholar
  10. 10.
    Perea EJ, Prados R, Miguel Cde, Aznar J. Single-dose ciprofloxacin treatment of gonococcal urethritis. Proc 1st Int Ciprofloxacin Workshop, Leverkusen 6–8 November 1985. Excerpta Medica, 1986.Google Scholar
  11. 11.
    Roddy RE, Hunter Handsfield H, Hook EW. Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men. Antimicrob Agents Chemother 1986;30:267–9.PubMedGoogle Scholar
  12. 12.
    Shahmanesh M, Shukla SR, Phillips I, Westwood A, Thin RN. Ciprofloxacin for treating urethral gonorrhoea in men. Genitourin Med 1986;62:86–7.PubMedGoogle Scholar
  13. 13.
    Loo PS, Ridgway GL, Oriel JD. Single dose ciprofloxacin for treating gonococcal infections in men. Genitourin Med 1985;61:302–5.PubMedGoogle Scholar
  14. 14.
    Fong IW, Hook EW, Stamm WE. Recent clinical trials in chlamydial infections: the value of quinolones. Infect Med Dis Lett Obstet Gynecol 1986;8:41–7.Google Scholar
  15. 15.
    Oriel JD. Ciprofloxacin in the treatment of gonorrhoea and non-gonococcal urethritis. J Antimicrob Chemother 1986;18:129–32.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1987

Authors and Affiliations

  • E. Stolz
    • 1
  • J. H. T. Wagenvoort
    • 2
  • A. H. van der Willigen
    • 1
  1. 1.Department of Dermatology and VenereologyUniversity Hospital Rotterdam-DijkzigtGD RotterdamThe Netherlands
  2. 2.Department of Clinical and Antimicrobial TherapyUniversity Hospital Rotterdam-DijkzigtGD RotterdamThe Netherlands

Personalised recommendations